Download full announcement
Renalytix AI plc (AIM: RENX), the AIM quoted developer of artificial intelligence-enabled diagnostics for kidney disease, announces that on 26 April 2019 the Company was notified that EKF Diagnostics plc (“EKF”) acquired 100,074 ordinary shares of £0.0025 each in the capital of the Company (the “Ordinary Shares”). Julian Baines, Christopher Mills and Richard Evans are each directors of, and directly and indirectly shareholders in, both the Company and EKF.
Following the above transaction, which was completed on 26 April 2019, at an average price of 123.81 pence per share, EKF’s interest in the Company is now in 2,677,981 Ordinary Shares, representing 4.98% of the Company’s issued share capital.
|Renalytix AI plc||www.renalytixai.com|
|James McCullough, CEO||Via Walbrook PR or|
Tel: +1 646 397 3970
|Stifel (Nominated Adviser & Joint Broker)||Tel: 020 7710 7600|
Alex Price / Jonathan Senior / Ben Maddison (Investment Banking)
|N+1 Singer (Nominated Adviser & Broker)||Tel: 020 7496 3000|
|Aubrey Powell / James White / George Tzimas (Corporate Finance)|
Tom Salvesen / Mia Gardner (Corporate Broking)
|Walbrook PR Limited||Tel: 020 7933 8780|
|Mob: 07980 541 893|
07584 391 303
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant.
RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|1||Details of the person discharging managerial responsibilities / person closely associated|
|a)||Name||EFK Diagnostics plc (“EKF”)|
|2||Reason for the notification|
|a)||Position/status||Julian Baines, Christopher Mills and Richard Evans are each directors of, and directly and indirectly shareholders in, both the Company and EKF|
|b)||Initial notification /Amendment||Initial Notification|
|3||Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor|
|4||Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted|
|a)||Description of the financial instrument, type of instrument Identification code||Ordinary shares of £0.0025 (“Ordinary Shares”) ISIN Code: GB00BYWL4Y04|
|b)||Nature of the transaction||Acquisition of shares|
|c)||Price(s) and volume(s)||Price(s) Volume(s) 125p 69,564 121.1 21,000 121.06 9,510|
|d)||Aggregated information – Aggregated volume – Price||N/A|
|e)||Date of the transaction||26 April 2019|
|f)||Place of the transaction||London Stock Exchange|